Vigil Neuroscience, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIGL research report →
Companywww.vigilneuro.com
Vigil Neuroscience, Inc. , a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.
- CEO
- Ivana Magovcevic-Liebisch
- IPO
- 2022
- Employees
- 69
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $375.71M
- P/E
- -5.26
- P/S
- 831.21
- P/B
- 9.29
- EV/EBITDA
- -4.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 22.57%
- Op Margin
- -16830.53%
- Net Margin
- -16129.87%
- ROE
- -122.87%
- ROIC
- -138.82%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-84,256,000 · -1.96%
- EPS
- $-2.07 · 2.82%
- Op Income
- $-89,683,000
- FCF YoY
- 27.89%
Performance & Tape
- 52W High
- $8.10
- 52W Low
- $1.31
- 50D MA
- $7.97
- 200D MA
- $3.80
- Beta
- 3.34
- Avg Volume
- 1.65M
Get TickerSpark's AI analysis on VIGL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 25 | Atlas Venture Fund XII, L.P. | sell | 1,027,978 |
| Aug 5, 25 | Thistle Mary | sell | 18,068 |
| Aug 5, 25 | Thistle Mary | sell | 12,155 |
| Aug 5, 25 | Thistle Mary | sell | 5,000 |
| Aug 5, 25 | Kaufmann Petra | sell | 144,000 |
| Aug 5, 25 | Kaufmann Petra | sell | 330,000 |
| Aug 5, 25 | Budd Haeberlein Samantha L. | sell | 18,068 |
| Aug 5, 25 | Budd Haeberlein Samantha L. | sell | 30,694 |
| Aug 5, 25 | Budd Haeberlein Samantha L. | sell | 12,000 |
| Aug 5, 25 | Ziolkowski Jennifer Lynn | sell | 135,000 |
Our VIGL Coverage
We haven't published any research on VIGL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIGL Report →